Back to Search
Start Over
Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma.
- Source :
-
Wiener klinische Wochenschrift [Wien Klin Wochenschr] 2012 Feb; Vol. 124 (3-4), pp. 104-10. Date of Electronic Publication: 2011 Sep 22. - Publication Year :
- 2012
-
Abstract
- Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) is one of the most frequently applied standard treatments for this disease. The role for TACE is fairly well defined within the most widely used treatment algorithm for HCC, die Barcelona Clinic Liver Cancer (BCLC) staging system and treatment algorithm. But no general treatment algorithm will go into the technical details of any procedure and several patients will not fit ideally into the patient groups predefined in BCLC or any other treatment algorithm. Furthermore, indications and contraindications sometimes are viewed differently by the various medical specialties involved in taking care of such patients. We present here the joint expert position statement of the Austrian Societies of Gastroenterology and Hepatology (ÖGGH), Interventional Radiology (ÖGIR), Hematology and Oncology (ÖGHO), and Surgical Oncology (ASSO) on the technical aspects, indications, and contraindication for the use of TACE in the management of HCC.
Details
- Language :
- English
- ISSN :
- 1613-7671
- Volume :
- 124
- Issue :
- 3-4
- Database :
- MEDLINE
- Journal :
- Wiener klinische Wochenschrift
- Publication Type :
- Academic Journal
- Accession number :
- 21935644
- Full Text :
- https://doi.org/10.1007/s00508-011-0056-2